Protein Levels Could Replace Genetic Tests for Detecting ARID1A Mutations

Protein Levels Could Replace Genetic Tests for Detecting ARID1A Mutations
A laboratory technique that measures protein levels in tissue samples — called immunohistochemistry (IHC) — is a quicker and less expensive alternative to detect ARID1A mutations in patients with ovarian  and other gynecological cancers, a new study shows. As more treatments are being tested for patients with ARID1A mutations, the approach may allow patients to be classified more accurately for participation in clinical trials. The study, “Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers,” was published in the Journal of Pathology. ARID1A, a gene that plays a role in suppressing tumor formation, is commonly mutated in patients with cancers of the ovary and endometrium. It also is an important biomarker for new therapies that specifically target patients with ARID1A defects. In fact, there are a number of clinical trials currently assessing ARID1A mutation status as part of the study. The gold standard for accurately detecting mutations is gene sequencing. However, sequencing is an expensive technique that is not always available. One of the other ways researchers can determine mutational status is by conducting (IHC) test. IHC uses protein stains in a sample of tissue using antibodies that are directed toward that s
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *